Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

NCT: NCT04502316 · ACTIVE_NOT_RECRUITING

NCT IDNCT04502316
StatusACTIVE_NOT_RECRUITING
Start Date2020-06-26
Completion2028-06

Brief Summary

The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.

Frequently Asked Questions

What is Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)?

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry) is a clinical trial registered under NCT04502316. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04502316?

The current status of NCT04502316 (Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)) is: ACTIVE_NOT_RECRUITING.

When did Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry) start?

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry) started on 2020-06-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.